Eleonora Georgeta Lad
Associate Professor of Ophthalmology
Eleonora (Nora) Lad, MD, PhD is a clinician scientist and retinal ophthalmologist with the primary goal of developing novel strategies for early diagnosis and treatment of age-related macular degeneration (AMD).
Dr. Lad specializes in the diagnosis and treatment of macular diseases, such as AMD, diabetic retinopathy, and retinal vascular diseases. She is involved in clinical trials and innovative therapies for the treatment of macular diseases. Dr. Lad is committed to providing the highest level of evidence-based patient care.
Dr. Lad’s career goal is to translate her doctoral training in neuroscience into developing innovative diagnostic and therapeutic approaches for AMD. Her research interests are the following:
1) investigating the role of neuroinflammation and abnormal protein aggregates in the pathogenesis of AMD and developing relevant treatments
2) visual function testing in dry AMD with the goal of establishing functional endpoints for future clinical studies in early AMD
3) elucidating the use of novel retinal imaging biomarkers for early diagnosis of aging diseases (AMD and Alzheimer’s disease), including through the use of artificial intelligence (machine and deep learning). On these studies, she is collaborating with an interdisciplinary team of investigators from Ophthalmology, Geriatrics, Computer Engineering, Biomedical Engineering, Neurology and Alzheimer’s Disease Research Center.
Dr. Lad is the recipient of the Patient-Oriented Research Career Development (K23) Award from the National Eye Institute, the 2016 Research to Prevent Blindness Ernest & Elizabeth Althouse Special Scholar Award, the 2016 ARVO/Alcon Early Career Clinician-Scientist Research Award, Heed Foundation award, and Duke Institute for Brain Sciences incubator award, among others. She is a member of the Macula Society, Retina Society, American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, International Society for Eye Research, Society of Heed Fellows, Society for Neuroscience and American Society for Neural Therapy and Repair.
ARIS: AMD Ryan Initiative Study awarded by Emmes Corp (Principal Investigator). 2019 to 2023
APL2-304 awarded by Apellis Pharmaceuticals, Inc (Principal Investigator). 2018 to 2022
Lightside III CSP005 awarded by LumiThera, Inc. (Principal Investigator). 2019 to 2022
Pathogenesis of age-related macular degeneration awarded by Novartis Pharma AG (Co-Principal Investigator). 2017 to 2020
BIMD - Collaborate Research Agreement awarded by Boehringer Ingelheim Pharmaceuticals, Inc. (Principal Investigator). 2018 to 2020
Monocytes in Dry Age-Related Macular Degeneration awarded by National Institutes of Health (Principal Investigator). 2016 to 2019
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE¿SPONSORED STUDY awarded by F. Hoffmann-La Roche Ltd (Principal Investigator). 2016 to 2019
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA) - FILLY awarded by Apellis Pharmaceuticals, Inc (Principal Investigator). 2015 to 2019
The role of a macrophage chemotactic factor in AMD awarded by BrightFocus Foundation (Collaborator). 2015 to 2017
NEI Mentored Clinical Scientist Development Program Award (K12) awarded by National Institutes of Health (Scholar). 2004 to 2016
Ong, Sally S., et al. “Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy.” J Neurol, vol. 266, no. 7, July 2019, pp. 1566–77. Pubmed, doi:10.1007/s00415-018-9028-z. Full Text
Chew, Emily Y., et al. “Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.” Ophthalmology, vol. 126, no. 4, Apr. 2019, pp. 540–49. Pubmed, doi:10.1016/j.ophtha.2018.09.041. Full Text
Chan, Victor T. T., et al. “Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis.” Ophthalmology, vol. 126, no. 4, Apr. 2019, pp. 497–510. Pubmed, doi:10.1016/j.ophtha.2018.08.009. Full Text
Margeta, Milica A., et al. “CD163+ macrophages infiltrate axon bundles of postmortem optic nerves with glaucoma.” Graefes Arch Clin Exp Ophthalmol, vol. 256, no. 12, Dec. 2018, pp. 2449–56. Pubmed, doi:10.1007/s00417-018-4081-y. Full Text
Ong, Sally S., et al. “Controversies and Future Directions of Ocular Biomarkers in Alzheimer Disease.” Jama Neurol, vol. 75, no. 6, June 2018, pp. 650–51. Pubmed, doi:10.1001/jamaneurol.2018.0602. Full Text
Thompson, Atalie C., et al. “Review of Ophthalmology Medical Professional Liability Claims in the United States from 2006 through 2015.” Ophthalmology, vol. 125, no. 5, May 2018, pp. 631–41. Pubmed, doi:10.1016/j.ophtha.2017.11.018. Full Text
Cocce, Kimberly J., et al. “Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.” Am J Ophthalmol, vol. 189, May 2018, pp. 127–38. Pubmed, doi:10.1016/j.ajo.2018.02.012. Full Text
Horne, Alexandra J., et al. “Relating Sensory, Cognitive, and Neural Factors to Older Persons' Perceptions about Happiness: An Exploratory Study.” J Aging Res, vol. 2018, 2018, p. 4930385. Pubmed, doi:10.1155/2018/4930385. Full Text Open Access Copy
Thompson, Atalie C., et al. “Association of Low Luminance Questionnaire With Objective Functional Measures in Early and Intermediate Age-Related Macular Degeneration.” Invest Ophthalmol Vis Sci, vol. 59, no. 1, Jan. 2018, pp. 289–97. Pubmed, doi:10.1167/iovs.17-22528. Full Text
Lad, Eleonora M., et al. “Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer's disease.” Plos One, vol. 13, no. 2, 2018, p. e0192646. Pubmed, doi:10.1371/journal.pone.0192646. Full Text
Lad, Eleonora M., et al. “Identity of pigmented subretinal cells in age-related macular degeneration.” Graefes Arch Clin Exp Ophthalmol, vol. 254, no. 6, June 2016, pp. 1239–41. Pubmed, doi:10.1007/s00417-015-3249-y. Full Text
Lad, Eleonora M., et al. “Retinal glioneuronal hamartoma in neurofibromatosis type 1.” Arch Ophthalmol, vol. 130, no. 10, Oct. 2012, pp. 1335–37. Pubmed, doi:10.1001/archophthalmol.2012.2250. Full Text
Lad, E. M., et al. “Erratum: Retinopathy of prematurity in the United States (British Journal of Ophthalmology (2008) 92 (320-5) DOI: 10.1136/bjo.2007.126201corr1).” British Journal of Ophthalmology, vol. 94, no. 9, 1 Jan. 2010, p. 1268. Scopus, doi:10.1136/bjo.2007.126201corr1. Full Text